resources
From continuing education to podcasts by our team of experts, keep up with the latest at Children's Health.
RESEARCH & INNOVATION
transforming pediatric health care
Hematology & Oncology
Fertility preservation in pediatric oncology: A multidisciplinary approach to care and survivorship
Pediatric fertility preservation now includes advanced options giving hope to even the youngest patients. Our experts share their insights, based on years of experience at the leading edge of this rapidly evolving field.
Hematology & Oncology, +1 more
Groundbreaking pediatric cardio-oncology program transforming care
The Pediatric Cardio-Oncology Program at Children’s Health is one of the first in the nation offering a dedicated clinic focused on protecting the heart health of children battling cancer or in remission.
Hematology & Oncology
When should you use MEK inhibitors for neurofibromatosis type 1?
Learn the guidelines for evaluating when a MEK inhibitor is right for your NF type 1 patient – from an expert who helped write them.
Hematology & Oncology
How to Spot Pediatric Cancer Early and Know When to Refer
Learn how to distinguish pediatric cancer symptoms from common conditions, the appropriate workup if you suspect cancer and when to refer to the ER vs a cancer center.
Hematology & Oncology, +1 more
CAR-T cell Therapy
Children’s Health and UT Southwestern are proud to be among 25 sites in the United States, European Union, Canada, Australia and Japan that participated in the Novartis-sponsored ELIANA study of a groundbreaking cancer therapy.
Hematology & Oncology
Using patient-derived xenografts to pursue targeted pediatric cancer therapies
Children’s Health and UT Southwestern part of a research collaboration that’s using patient-derived xenografts to pursue targeted therapies for an array of pediatric cancers.
Hematology & Oncology
Bringing fertility preservation to the forefront of pediatric cancer care
We’ve built a multidisciplinary team and standardized protocols to overcome challenges of oncofertility care and help kids have a brighter future beyond cancer.
Hematology & Oncology
Using intra-arterial chemotherapy to treat retinoblastoma in children
Discover how intra-arterial chemotherapy treats retinoblastoma and improves the chances of saving children’s eyes. Our experts discuss this innovative treatment.
Hematology & Oncology
NCT04690322
Each patient will be randomly assigned to receive either extended half-life factor VIII based replacement therapy or non-FVIII based replacement therapy, which are both standard of care treatment for persons with Hemophilia A.
Hematology & Oncology
AHOD1331, A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
Learn about our randomized phase III study of brentuximab vedotin for newly diagnosed high-risk classical hodgkin lymphoma (cHL) in children and adolescents.
Hematology & Oncology
AALL1331, Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Learn about the risk-stratified randomized phase III testing of blinatumomab in the first relapse of childhood B-lymphoblastic leukemia at Children's Health.
Hematology & Oncology
AEWS1221, Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
Learn about our IGF-1R monoclonal antibody ganitumab and multiagent chemotherapy treatment trial for newly diagnosed metastatic ewing sarcoma patients.
Hematology & Oncology
AALL1231, A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Learn about our phase 3 randomized trial investigating bortezomib on a modified augmented BFM backbone in newly diagnosed T-Lymphoblastic Leukemia and Lymphoma.
Hematology & Oncology
NCT05776069
This is a multi-center, Phase 1a study to assess the safety, tolerability, PK, and PD of VGA039 following single IV or SC dose administration in healthy subjects and subjects with VWD.
Hematology & Oncology
NCT05405426
Trial of Indication-based Transfusion of Red Blood Cells in ECMO, is a multicenter, prospective, randomized clinical trial.
Hematology & Oncology
NCT05662319
In standard of care (SOC) period, participants will receive on-demand or prophylactic treatment with clotting factor concentrates (CFCs) or bypassing agents (BPAs) for 6 months (from Day -168 to Day -1).